Literature DB >> 15068837

Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.

Kemal Kismet1, M Turan Akay, Osman Abbasoglu, Aygün Ercan.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used therapeutic agents in the treatment of pain, inflammation and fever. They may also have a role in the management of cancer prevention, Alzheimer's disease and prophylaxis against cardiovascular disease. These drugs act primarily by inhibiting cyclooxygenase enzyme, which has two isoforms, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Selective COX-2 inhibitors provide potent anti-inflammatory and analgesic effects without the side effects of gastric and renal toxicity and inhibition of platelet function. Celecoxib is a potent COX-2 inhibitor being developed for the treatment of rheumatoid arthritis and osteoarthritis. Chemoprevention is the use of pharmacological or natural agents to prevent, suppress, interrupt or reverse the process of carcinogenesis. For this purpose, celecoxib is being used for different cancer types. The effects of NSAIDs on tumor growth remain unclear, but are most likely to be multifocal. In this article, we reviewed COX-2 selectivity, the pharmacological properties of celecoxib, the use of celecoxib for cancer prevention and the mechanisms of chemoprevention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15068837     DOI: 10.1016/j.cdp.2003.12.005

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  22 in total

1.  In vitro characterization of chitosan gels for buccal delivery of celecoxib: influence of a penetration enhancer.

Authors:  Yara Peluso Cid; Vinícius Pedrazzi; Valéria Pereira de Sousa; Maria Bernadete Riemma Pierre
Journal:  AAPS PharmSciTech       Date:  2011-12-09       Impact factor: 3.246

2.  Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Authors:  Sadegh Amini; Martha H Viera; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

3.  Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma.

Authors:  C T Tong; S A Howard; H R Shah; K R Van Quill; E T Lin; H E Grossniklaus; J M O'Brien
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

4.  Celecoxib extends C. elegans lifespan via inhibition of insulin-like signaling but not cyclooxygenase-2 activity.

Authors:  Tsui-Ting Ching; Wei-Chung Chiang; Ching-Shih Chen; Ao-Lin Hsu
Journal:  Aging Cell       Date:  2011-04-07       Impact factor: 9.304

5.  Cyclooxygenase-2 promotes ovarian cancer cell migration and cisplatin resistance via regulating epithelial mesenchymal transition.

Authors:  Lin Deng; Ding-Qing Feng; Bin Ling
Journal:  J Zhejiang Univ Sci B       Date:  2020 Apr.       Impact factor: 3.066

6.  A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation.

Authors:  Aline Correa Abrahao; Rogerio M Castilho; Cristiane H Squarize; Alfredo A Molinolo; Decio dos Santos-Pinto; J Silvio Gutkind
Journal:  Oral Oncol       Date:  2010-10-14       Impact factor: 5.337

7.  Quantitation of celecoxib and four of its metabolites in rat blood by UPLC-MS/MS clarifies their blood distribution patterns and provides more accurate pharmacokinetics profiles.

Authors:  Yong Ma; Song Gao; Ming Hu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-07-19       Impact factor: 3.205

Review 8.  The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells.

Authors:  Mathias Gehrmann; Jürgen Radons; Michael Molls; Gabriele Multhoff
Journal:  Cell Stress Chaperones       Date:  2008-02-05       Impact factor: 3.667

9.  Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model.

Authors:  Chao-Hung Kuo; Huang-Ming Hu; Pei-Yun Tsai; I-Chen Wu; Sheau-Fang Yang; Lin-Li Chang; Jaw-Yuan Wang; Chang-Ming Jan; Wen-Ming Wang; Deng-Chyang Wu
Journal:  World J Gastroenterol       Date:  2009-10-21       Impact factor: 5.742

10.  Use of Non-steroidal Anti-inflammatory Drugs for Chemoprevention of Inflammation-induced Prostate Cancer.

Authors:  Bilge Debeleç Bütüner; Mert Burak Öztürk
Journal:  Turk J Pharm Sci       Date:  2017-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.